198 related articles for article (PubMed ID: 26910909)
21. Fas/APO-1 (CD95) expression in myelodysplastic syndromes.
Lepelley P; Grardel N; Erny O; Iaru T; Obein V; Cosson A; Fenaux P
Leuk Lymphoma; 1998 Jul; 30(3-4):307-12. PubMed ID: 9713962
[TBL] [Abstract][Full Text] [Related]
22. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
23. Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.
Marisavljević D; Rolović Z; Sefer D; Basara N; Ilić D; Bosković D; Colović M
Med Oncol; 2002; 19(4):249-59. PubMed ID: 12512919
[TBL] [Abstract][Full Text] [Related]
24. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Castelli R; Schiavon R; Rossi V; Deliliers GL
Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
[TBL] [Abstract][Full Text] [Related]
25. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
Aoki A; Shibata A
Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
[TBL] [Abstract][Full Text] [Related]
26. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
27. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors.
Backx B; Broeders L; Touw I; Löwenberg B
Leukemia; 1993 Jan; 7(1):75-9. PubMed ID: 8418382
[TBL] [Abstract][Full Text] [Related]
28. Erythroid and myeloid maturation patterns related to progenitor assessment in the myelodysplastic syndromes.
Dörmer P; Schalhorn A; Wilmanns W; Hershko C
Br J Haematol; 1987 Sep; 67(1):61-6. PubMed ID: 3663522
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Toma A; Kosmider O; Chevret S; Delaunay J; Stamatoullas A; Rose C; Beyne-Rauzy O; Banos A; Guerci-Bresler A; Wickenhauser S; Caillot D; Laribi K; De Renzis B; Bordessoule D; Gardin C; Slama B; Sanhes L; Gruson B; Cony-Makhoul P; Chouffi B; Salanoubat C; Benramdane R; Legros L; Wattel E; Tertian G; Bouabdallah K; Guilhot F; Taksin AL; Cheze S; Maloum K; Nimuboma S; Soussain C; Isnard F; Gyan E; Petit R; Lejeune J; Sardnal V; Renneville A; Preudhomme C; Fontenay M; Fenaux P; Dreyfus F
Leukemia; 2016 Apr; 30(4):897-905. PubMed ID: 26500139
[TBL] [Abstract][Full Text] [Related]
30. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
31. Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R.
Li B; Liu J; Qu S; Gale RP; Song Z; Xing R; Liu J; Ren Y; Xu Z; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Hu N; Cai W; Zhang P; Huang G; Xiao Z
Oncotarget; 2016 Oct; 7(42):68023-68032. PubMed ID: 27655727
[TBL] [Abstract][Full Text] [Related]
32. BOK promotes erythropoiesis in a mouse model of myelodysplastic syndrome.
Kang SH; Perales O; Michaud M; Katz SG
Ann Hematol; 2019 Sep; 98(9):2089-2096. PubMed ID: 31203423
[TBL] [Abstract][Full Text] [Related]
33. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
34. Dyserythropoiesis of myelodysplastic syndromes.
Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
[TBL] [Abstract][Full Text] [Related]
35. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
36. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.
Huang H; Xu C; Gao J; Li B; Qin T; Xu Z; Ren S; Zhang Y; Jiao M; Qu S; Pan L; Hu N; Liu J; Cai W; Zhang Y; Wu D; Zhang P; Gale RP; Huang G; Zhou J; Shi L; Xiao Z
Blood Cancer J; 2020 Aug; 10(8):83. PubMed ID: 32801296
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin.
Sibon D; Coman T; Rossignol J; Lamarque M; Kosmider O; Bayard E; Fouquet G; Rignault R; Topçu S; Bonneau P; Bernex F; Dussiot M; Deroy K; Laurent L; Callebert J; Launay JM; Georgin-Lavialle S; Courtois G; Maroteaux L; Vaillancourt C; Fontenay M; Hermine O; Côté F
Cell Rep; 2019 Mar; 26(12):3246-3256.e4. PubMed ID: 30893598
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis.
Hopfer O; Nolte F; Mossner M; Komor M; Kmetsch A; Benslasfer O; Reissmann M; Nowak D; Hoelzer D; Thiel E; Hofmann WK
Eur J Haematol; 2012 Feb; 88(2):144-53. PubMed ID: 21967505
[TBL] [Abstract][Full Text] [Related]
39. Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock.
Claessens YE; Fontenay M; Pene F; Chiche JD; Guesnu M; Hababou C; Casadevall N; Dhainaut JF; Mira JP; Cariou A
Am J Respir Crit Care Med; 2006 Jul; 174(1):51-7. PubMed ID: 16574939
[TBL] [Abstract][Full Text] [Related]
40. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.
Hopfer O; Komor M; Koehler IS; Freitag C; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Leuk Res; 2009 Mar; 33(3):434-42. PubMed ID: 18829110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
